DK0813873T3 - Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere - Google Patents

Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere

Info

Publication number
DK0813873T3
DK0813873T3 DK97201853T DK97201853T DK0813873T3 DK 0813873 T3 DK0813873 T3 DK 0813873T3 DK 97201853 T DK97201853 T DK 97201853T DK 97201853 T DK97201853 T DK 97201853T DK 0813873 T3 DK0813873 T3 DK 0813873T3
Authority
DK
Denmark
Prior art keywords
serotin
mirtazapine
selective
pharmaceutical composition
reuptake inhibitors
Prior art date
Application number
DK97201853T
Other languages
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0813873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0813873T3 publication Critical patent/DK0813873T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97201853T 1996-06-19 1997-06-17 Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere DK0813873T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
DK0813873T3 true DK0813873T3 (da) 2002-05-27

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97201853T DK0813873T3 (da) 1996-06-19 1997-06-17 Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere

Country Status (24)

Country Link
US (1) US5977099A (da)
JP (2) JP4925074B2 (da)
KR (1) KR100481254B1 (da)
CN (1) CN1132581C (da)
AR (1) AR007609A1 (da)
AT (1) ATE213159T1 (da)
AU (1) AU727851B2 (da)
BR (1) BR9703624A (da)
CA (1) CA2208199C (da)
CZ (1) CZ290691B6 (da)
DE (1) DE69710390T2 (da)
DK (1) DK0813873T3 (da)
ES (1) ES2172744T3 (da)
HU (1) HU225534B1 (da)
ID (1) ID17051A (da)
IL (1) IL121076A (da)
NO (1) NO313177B1 (da)
NZ (1) NZ328113A (da)
PL (1) PL188520B1 (da)
PT (1) PT813873E (da)
RU (1) RU2181287C2 (da)
SG (1) SG60073A1 (da)
TR (1) TR199700522A2 (da)
ZA (1) ZA975335B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DK1030667T3 (da) * 1997-11-14 2005-06-20 Akzo Nobel Nv Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
CA2396066A1 (en) * 2000-01-19 2001-07-26 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
IL150290A0 (en) * 2000-02-11 2002-12-01 Akzo Nobel Nv The use of mirtazapine for the treatment of sleep disorders
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
PL376832A1 (pl) * 2002-11-07 2006-01-09 Torrent Pharmaceuticals Ltd. Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) * 2003-02-21 2005-11-08 C Hinz Martin Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
CN101060860B (zh) * 2004-11-19 2013-07-17 Msd欧斯股份有限公司 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8768578B2 (en) 2009-06-09 2014-07-01 Sumitomo Heavy Industries, Ltd. Hybrid excavator and method of controlling hybrid excavator
WO2011059207A2 (en) * 2009-11-13 2011-05-19 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DK0431663T3 (da) * 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
ATE232384T1 (de) * 1997-10-03 2003-02-15 Cary Medical Corp Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion

Also Published As

Publication number Publication date
PT813873E (pt) 2002-06-28
KR980000447A (ko) 1998-03-30
HUP9701068A3 (en) 2000-07-28
SG60073A1 (en) 1999-02-22
KR100481254B1 (ko) 2005-09-12
DE69710390D1 (de) 2002-03-21
NO972816L (no) 1997-12-22
TR199700522A3 (tr) 1998-01-21
ID17051A (id) 1997-12-04
US5977099A (en) 1999-11-02
HK1006081A1 (en) 1999-02-12
JP2009137970A (ja) 2009-06-25
HUP9701068A2 (hu) 1998-08-28
NO313177B1 (no) 2002-08-26
CZ290691B6 (cs) 2002-09-11
DE69710390T2 (de) 2002-08-14
CZ187097A3 (cs) 1998-01-14
JP4925074B2 (ja) 2012-04-25
JPH1067663A (ja) 1998-03-10
CN1132581C (zh) 2003-12-31
ZA975335B (en) 1998-01-26
BR9703624A (pt) 1998-09-01
NZ328113A (en) 1999-09-29
PL320628A1 (en) 1997-12-22
HU9701068D0 (en) 1997-08-28
AU2612997A (en) 1998-01-08
ATE213159T1 (de) 2002-02-15
PL188520B1 (pl) 2005-02-28
CA2208199A1 (en) 1997-12-19
NO972816D0 (no) 1997-06-18
AU727851B2 (en) 2001-01-04
IL121076A (en) 2000-10-31
TR199700522A2 (xx) 1998-01-21
RU2181287C2 (ru) 2002-04-20
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
MX9704579A (es) 1998-07-31
ES2172744T3 (es) 2002-10-01
CN1173330A (zh) 1998-02-18
AR007609A1 (es) 1999-11-10
CA2208199C (en) 2006-10-24

Similar Documents

Publication Publication Date Title
NO972816L (no) Farmasöytisk blanding omfattende mirtazapin og én eller flere selektive serotonin-gjenopptaks-inhibitorer
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
NO20002359L (no) Adenosinderivater og farmasoytisk sammensetning inneholdende derivatene
NO984354D0 (no) Avisingsmiddel og anvendelse av dette
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO20006488D0 (no) Sammensetning og anvendelse
DK1112003T3 (da) Ny sammensætning og anvendelse
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO20011157L (no) Benzenderivater og farmasöytisk anvendelse derav
PT948483E (pt) Inibidores da farnesil-transferase
NO995513D0 (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
DK1068238T3 (da) Integrinheterodimer og subunit deraf
BR9509688A (pt) Composto e composição farmacêutica
DK0910369T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder
NO983802D0 (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmÕter
NO991749D0 (no) Sammensetninger til bruk i betong og betongprodukter fremstilt derav
NO20003142D0 (no) Substituerte isokinolin-derivater og anvendelse derav som antikrampemidler
NO995308D0 (no) Sammensetning og fremgangsmÕter som anvender en eutomer
DK1066261T3 (da) Pyridinderivat og farmaceutisk præparat indeholdende samme
DK1061955T3 (da) Polynukleotidsammensætning, fremstillingsmetode og anvendelse deraf
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO983556D0 (no) Formulering og anvendelse
NO306613B1 (no) Oligomer og farmasöytisk preparat omfattende denne
NO20015519D0 (no) Farmasöytisk sammensetning omfattende apokodein og/eller dets derivater